Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas

Otology and Neurotology

Volumn 30, Issue 4, 2009, Pages 559-565

  Juhász, Attila ^a,b   Sziklai, István ^a   Rákosy, Zsuzsa ^a,c   Ecsedi, Szilvia ^a   Ádány, Róza ^a,c   Balázs, Margit ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Greater Manchester Neurosciences Centre   (United Kingdom)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Apoptosis; Cholesteatoma; Immunofluorescence; Ki 67; MMP 9; Tenascin

Indexed keywords

CYTOKERATIN; FLUORESCENT DYE; GELATINASE B; KI 67 ANTIGEN; TENASCIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BONE DESTRUCTION; CELL PROLIFERATION; CHILD; CHOLESTEATOMA; CLINICAL ARTICLE; CONTROLLED STUDY; EXTERNAL AUDITORY CANAL; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SKIN; STAINING; STROMA;

ADOLESCENT; ADULT; APOPTOSIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CHILD; CHOLESTEATOMA, MIDDLE EAR; DISEASE PROGRESSION; EAR, MIDDLE; FEMALE; HUMANS; KERATINS; KI-67 ANTIGEN; MALE; MATRIX METALLOPROTEINASE 9; TEMPORAL BONE; TENASCIN;

EID: 68249091155     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e31819fe6ed     Document Type: Article

References (53)

1. Chae SW, Song JJ, Suh HK, Jung HH, Lim HH, Hwang SJ. Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium. Laryngoscope 2000;110:1898-1901
2. Peek FA, Huisman MA, Berckmans RJ, Sturk A, Van Loon J, Grote JJ. Lipopolysaccharide concentration and bone resorption in cholesteatoma. Otol Neurotol 2003;24:709-713 (Pubitemid 37122532)
3. Suzuki C, Ohtani I. Bone destruction resulting from rupture of a cholesteatoma sac: temporal bone pathology. Otol Neurotol 2004; 25:674-677 (Pubitemid 39223238)
4. Cinamon U, Kronenberg J, Benayahu D. Structural changes and protein expression in the mastoid bone adjacent to cholesteatoma. Laryngoscope 2000;110:1198-1203 (Pubitemid 30439782)
5. Hamzei M, Ventriglia G, Hagnia M, et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. Laryngoscope 2003;113:436-442 (Pubitemid 36292867)
6. Kuczkowski J, Pawelczyk T, Bakowska A, Narozny W,Mikaszewski B. Expression patterns of Ki-67 and telomerase activity in middle ear cholesteatoma. Oto Neurotol 2007;28:204-207 (Pubitemid 46175122)
7. Kojima H, Tanaka Y, Tanaka T, et al. Cell proliferation and apoptosis in human middle ear cholesteatoma. Arch Otolaryngol Head Neck Surg 1998;124:261-264 (Pubitemid 28141722)
8. Choufani G, Mahillon V, Decaestecker C, et al. Determination of the levels of expression of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope 1999;109:1825-1831 (Pubitemid 29533928)
9. Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003;123:377-382 (Pubitemid 36522788)
10. Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: a molecular and cellular puzzle. Am J Otol 1998;19:7-19.
11. Park HJ, Park K. Expression of Fas/APO-1 and apoptosis of keratinocytes in human cholesteatoma. Laryngoscope 1999;109: 613-616 (Pubitemid 29165913)
12. Motamed M, Powe D, Jones L, Kendall C, Banerjee AR. Are p53 and MIB-1 overexpressed in cholesteatoma? Clin Otolaryngol Allied Sci 2000;25:570-576
13. Schilling V, Holly A, Bujia J, Schulz P, Kastenbauer E. High levels of fibronectin in the stroma of aural cholesteatoma. Am J Otolaryngol 1995;16:232-235
14. Lang S, Schilling V, Wollenberg B, Mack B, Nerlich A. Localization of transforming growth factor-beta-expressing cells and comparison with major extracellular components in aural cholesteatoma. Ann Otol Rhinol Laryngol 1997;106:669-673 (Pubitemid 27353501)
15. Albino AP, Reed JA, Bogdany JK, Sassoon J, Desloge RB, Parisier SC. Expression of p53 protein in human middle ear cholesteatomas: pathogenetic implications. Am J Otol 1998;19:30-36 (Pubitemid 28070277)
16. Olszewska E, Chodynicki S, Chyczewski L, Rogowski M. Some markers of proliferative activity in cholesteatoma epithelium in adults. Med Sci Monit 2006;12:CR337-40. (Pubitemid 44186375)
17. Shinoda H, Huang CC. Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death. Laryngoscope 1995;105:1232-1237
18. Olszewska E, Chodynicki S, Chyczewski L. Apoptosis in the pathogenesis of cholesteatoma in adults. Eur Arch Otorhinolaryngol 2006;263:409-413
19. Huisman MA, De Heer E, Grote JJ. Survival signaling and terminal differentiation in cholesteatoma epithelium. Acta Otolaryngol 2007;127:424-429 (Pubitemid 46572874)
20. Miyao M, Shinoda H, Takahashi S. Caspase-3, caspase-8 and nuclear factor-kappaB expression in human cholesteatoma. Oto Neurotol 2006;27:8-13. (Pubitemid 43011084)
21. Ergun S, Carlsoo B, Zheng X. Apoptosis in meatal skin, cholesteatoma and squamous cell carcinoma of the ear. Clin Otolaryngol Allied Sci 1999;24:280-285 (Pubitemid 29397097)
22. Sakamoto T, Kondo K, Yamasoba T, Suzuki M, Sugasawa M, Kaga K. Overexpression of ErbB-2 protein in human middle ear cholesteatomas. Laryngoscope 2004;114:1988-1991 (Pubitemid 39539861)
23. Schonermark M, Mester B, Kempf HG, Blaser J, Tschesche H, Lenarz T. Expression of matrix-metalloproteinases and their inhibitors in human cholesteatomas. Acta Otolaryngol 1996;116:451-456 (Pubitemid 26184452)
24. Banerjee AR, James R, Narula AA. Matrix metalloproteinase-2 and matrix metalloproteinase-9 in cholesteatoma and deep meatal skin. Clin Otolaryngol Allied Sci 1998;23:345-347 (Pubitemid 28408397)
25. Schmidt M, Grunsfelder P, Hoppe F. Up-regulation of matrix metalloprotease-9 in middle ear cholesteatoma - correlations with growth factor expression in vivo? Eur Arch Otorhinolaryngol 2001;258:472-476 (Pubitemid 33141263)
26. Naim R, Sadick H, Schafer C, Hormann K. External auditory canal cholesteatoma: analysis of the integrity of the tissue structure. Int J Mol Med 2004;14:601-604
27. Banerjee AR, Jones JL, Birchall JP, Powe DG. Localization of matrix metalloproteinase 1 in cholesteatoma and deep meatal skin. Otol Neurotol 2001;22:579-581
28. Bardos H, Juhasz A, Repassy G, Adany R. Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 1998;80:767-772 (Pubitemid 28521720)
29. Juhasz A, Bardos H, Repassy G, Adany R. Characteristic distribution patterns of tenascin in laryngeal and hypopharyngeal cancers. Laryngoscope 2000;110:84-92. (Pubitemid 30046651)
30. Pearson CA, Pearson D, Shibahara S, Hofsteenge J, Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-beta. Embo J 1988;7:2977-2982
31. Yokosaki Y, Monis H, Chen J, Sheppard D. Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J Biol Chem 1996;271:24144-24150 (Pubitemid 126749859)
32. Sudhoff H, Bujia J, Borkowshi G, et al. Basement membrane in middle ear cholesteatoma. Immunohistochemical and ultrastructural observations. Ann Otol Rhinol Laryngol 1996;105:804-810 (Pubitemid 26346564)
33. Chole RA, Hughes RM, Faddis BT. Keratin particle-induced osteolysis: a mouse model of inflammatory bone remodeling related to cholesteatoma. J Assoc Res Otolaryngol 2001;2:65-71.
34. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993;28:500-510
35. Grillet B, Dequeker J, Paemen L, Van Damme B, Opdenakker G. Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody. Br J Rheumatol 1997;36:744-747 (Pubitemid 27348196)
36. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345-355 (Pubitemid 27465596)
37. Nielsen BS, Timshel S, Kjeldsen L, et al. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996;65:57-62. (Pubitemid 26027538)
38. Shibosawa E, Tsutsumi K, Takakuwa T, Takahashi S. Stromal expression of matrix metalloprotease-9 in middle ear cholesteatomas. Am J Otol 2000;21:621-624 (Pubitemid 30683234)
39. Forster C, Kahles T, Kietz S, Drenckhahn D. Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol 2007;580:937-949 (Pubitemid 46915250)
40. Chu SC, Yang SF, Lue KH, Hsieh YS, Li TJ, Lu KH. Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis. Clin Chim Acta 2008;387:90-96 (Pubitemid 350050939)
41. Burggraf D, Trinkl A, Dichgans M, Hamann GF. Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol Dis 2007;25:506-513 (Pubitemid 46304240)
42. Mackie EJ, Tucker RP, Halfter W, Chiquet-Ehrismann R, Epperlein HH. The distribution of tenascin coincides with pathways of neural crest cell migration. Development 1988;102:237-250 (Pubitemid 18063190)
43. Adany R, Toida M, Takami T. Arborizing tenascin network under the rapidly proliferating epithelium of epulis. J Histochem Cytochem 1993;41:1717-1718 (Pubitemid 23317119)
44. Karja V, Syrjanen K, Syrjanen S. Collagen IV and tenascin immuno-reactivity as prognostic determinant in benign and malignant salivary gland tumors. Acta Otolaryngol 1995;115:569-575
45. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996;56:182-189 (Pubitemid 26010398)
46. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RC. Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 2002;38:332-336 (Pubitemid 34655686)
47. Sedele M, Karaveli S, Pestereli HE, et al. Tenascin expression in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol 2002;21:161-166 (Pubitemid 34260637)
48. Lochter A, Vaughan L, Kaplony A, Prochiantz A, Schachner M, Faissner A. J1/tenascin in substrate-bound and soluble form displays contrary effects on neurite outgrowth. J Cell Biol 1991;113: 1159-1171 (Pubitemid 21909746)
49. Wehrle-Haller B, Chiquet M. Dual function of tenascin: simultaneous promotion of neurite growth and inhibition of glial migration. J Cell Sci 1993;106:597-610. (Pubitemid 23309078)
50. Filenius S, Tervo T, Virtanen I. Production of fibronectin and tenascin isoforms and their role in the adhesion of human immortalized corneal epithelial cells. Invest Ophthalmol Vis Sci 2003;44: 3317-3325 (Pubitemid 36909765)
51. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 2003;105:53-60. (Pubitemid 36418485)
52. Ilunga K, Nishiura R, Inada H, et al. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin- C enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol 2004;85:373-379 (Pubitemid 39647366)
53. Bujia J, Holly A, Schilling V, Negri B, Pitzke P, Schulz P. Aberrant expression of epidermal growth factor receptor in aural cholesteatoma. Laryngoscope 1993;103:326-329 (Pubitemid 23073333)